Moderna, based in Massachusetts, Cambridge, has announced that it will start the third phase of its mRNA-1273, the experimental site for its COVID-19 vaccine.
The company is a leader in research into the potential COVID-19 vaccine, which has killed over 423,000 people worldwide. There have been several research institutes and organizations that have also joined the race to find a possible cure or prevention of the highly infectious virus that threatens the global economy. But Moderna with his RNA vaccine is now ahead of everyone.
They administered the first patient with the first dose in the phase 1 study on March 16 and the second dose on April 23.
The vaccine that Moderna is scheduled to test on over 30,000 people in July, mRNA-1273, is a vaccine that is expected to be effective against SARS-CoV-2.
The vaccine is a new type of technology that contains a portion of the messenger that encodes the protein associated with the virus.
When vaccine is injected into a person, the mRNA travels into the subject’s cells, where it produces the protein.
The body’s immune system then reacts to the protein produced as a virus and develops the immune system that it uses when it comes into contact with the real virus.
The phase 3 trial is ideal for vaccine approval and will involve approximately 30,000 volunteers. The study randomized the placebo or vaccine on a 1: 1 scale. The expected ultimate goal is the prevention of COVID-19.
The optimal dosage was set at 100 micrograms based on the results of the first phase. The company said they have enough doses to use in phase 3 studies.
If the vaccine is approved, the company will be able to produce around 500 million to 1 billion doses annually from next year.
Tal Zaks, Moderna’s chief medical officer, said they look forward to starting their July Phase 3 trial of mRNA-1273 with around 30,000 participants from July.
He added that the company is committed to driving clinical development of mRNA-1273 as safely and as quickly as possible to show that the vaccine has a significant ability to address the risks of COVID-19 that cause respiratory disease.
In phase two, the focus was on the safety, reactogenicity, and immunogenicity of this vaccine, in which it was administered to participants aged 18 to 54 years.
The company plans to enroll 600 healthy patients in two cohorts of adults in this age group of older adults aged 55 and over. Participants receive either a placebo or a dose of 50 micrograms for both vaccinations and are followed up 12 months after the second dose.
While it remains a wish for anybody in any country with a confirmed COVID-19 case for the possible cure or vaccine be announced sooner or later, Moderna sparks some hopes in the minds of many.
However, the demand should force bypassing the set guidelines in developing a vaccine that can result in a problem itself than a solution.
Wayne Sims is the Lead Editor for Chroniclex with 12 years of experience. Wayne has been working for Many Large Online Publications for nearly a decade and has published his articles in many prints and digital publications including Erieview Newsstand, Bond Court News and Private Entertainment. When Wayne is not busy writing She likes stitching.